Group 1 - Shopify's stock increased by 10.3% after reporting Q4 revenue that exceeded expectations [1] - Lyft's stock fell by 16.1% due to Q4 revenue falling short of expectations and weak guidance for the first quarter [1] - Mattel's stock dropped by 29.4% as the company projected annual profits below expectations [1] Group 2 - Moderna's stock declined by 9.1% after the FDA rejected its application for the review of an experimental flu vaccine [1] - Kraft Heinz's stock fell by 5.8% as the company announced a pause on its split plan [1] - Kingsoft Cloud's stock rose by 9.7% as Goldman Sachs anticipates benefits from Xiaomi's continued investment in AI [1]

Core Viewpoint - Moderna's experimental flu vaccine has successfully met the primary endpoint in its Phase 3 clinical trial, leading to a pre-market stock increase of over 6% [1]. Stock Performance - Moderna's stock price rose by 6.22% in pre-market trading, reaching $28.650 [1]. - The stock's previous closing price was $27.540, indicating a significant upward movement [1]. - The stock's trading volume in pre-market was approximately 28,900 shares, with a total market capitalization of $10.504 billion [1]. Financial Metrics - The stock has a price-to-earnings (P/E) ratio of loss, reflecting its current financial performance [1]. - The stock's 52-week high was $129.390, while the 52-week low was $23.150, showing substantial volatility [1]. - The average price in pre-market trading was $28.428, with a trading range of $27.680 to $29.180 [1].